Journal ArticleDOI
HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact
Natalie Turner,Angelo Di Leo +1 more
TLDR
Evidence of HER2 discordance leading to alterations in patient outcomes is limited, highlighting the need for further research in this area and suggesting that a more pragmatic approach to the decision to rebiopsy may be appropriate.About:
This article is published in Cancer Treatment Reviews.The article was published on 2013-12-01. It has received 70 citations till now. The article focuses on the topics: Breast cancer.read more
Citations
More filters
Journal ArticleDOI
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
Willemijne A. M. E. Schrijver,Karijn P M Suijkerbuijk,Carla H. van Gils,Elsken van der Wall,Cathy B. Moelans,Paul J. van Diest +5 more
TL;DR: Receptor conversion for ERα, PR, and HER2 occurs frequently in the course of disease progression in breast cancer, and large prospective studies assessing the impact of receptor conversion on treatment efficacy and survival are needed.
Journal ArticleDOI
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Christopher D. Hart,Ilenia Migliaccio,Luca Malorni,Cristina Guarducci,Laura Biganzoli,Angelo Di Leo +5 more
TL;DR: The current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer is examined, how to tackle these therapeutic challenges are discussed and suggestions for the optimal management of this patient population are provided.
Journal ArticleDOI
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.
TL;DR: The results indicate that HER2/neu overexpression occurred in 14% of the advanced gallbladder cancer cases, which indicates that this subgroup of patients may benefit from inhibitors of the HER2-neu pathway.
Journal ArticleDOI
Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy.
Patrícia M. R. Pereira,Sai Kiran Sharma,Lukas M. Carter,Kimberly J. Edwards,Jacob Pourat,Ashwin Ragupathi,Yelena Y. Janjigian,Jeremy C. Durack,Jeremy C. Durack,Jason S. Lewis +9 more
TL;DR: The authors show that caveolin-1 (CAV1) regulates HER2 density at the cell membranes and that CAV1 gene knockdown or protein depletion via the cholesterol modulator lovastatin, increases trastuzumab binding and anti-tumor activity.
References
More filters
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou,Suleiman Massarweh,C. Kent Osborne,A. E. Wakeling,Simale Ali,Heidi L. Weiss,Rachel Schiff +6 more
TL;DR: Gefitinib pretreatment eliminated tamoxifen's agonist effects, restored its antitumor activity both in vitro and in vivo in MCF-7/HER2-18 cells, and revealed molecular cross-talk between the ER and HER2 pathways was increased.
Journal Article
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Richard J. Pietras,M. Jane Arboleda,David M. Reese,Wongvipat N,Pegram,Lillian Ramos,Cornelia M. Gorman,Parker Mg,Mark X. Sliwkowski,Dennis J. Slamon +9 more
TL;DR: It is demonstrated that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen.
Journal ArticleDOI
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fatima Cardoso,Ana Costa,Larry Norton,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,Laura Biganzoli,Kimberly L. Blackwell,Maria João Cardoso,Tanja Cufer,N.S. El Saghir,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Sharon H. Giordano,Joseph Gligorov,A. Goldhirsch,Nadia Harbeck,Nehmat Houssami,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Stella Kyriakides,U. N. Lin,Musa Mayer,S. D. Merjaver,E. B. Nordström,Olivia Pagani,A.H. Partridge,Frédérique Penault-Llorca,Martine Piccart,Hope S. Rugo,George W. Sledge,Christoph Thomssen,L.J. van 't Veer,Daniel A. Vorobiof,Conny Vrieling,N. West,Bo Xu,Eric P. Winer +42 more
TL;DR: Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease, although the range is wide, and survival may be longer for patients treated in specialized institutions and within each country.
Related Papers (5)
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more